Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Equal number of patients in both groups died.
However, more patients were treated with Brilacidin.
By definition, As a percentage of patients treated, the mortality was decreased in the Brilacidin group.
Secondary end points can be very valuable in designing future studies if safety criteria was met.
Of course, I would have been more ecstatic if primary endpoint was met.
The overall mortality rate (6.67%) in the trial was approximately one-half of what is typically observed in this patient population.
In the trial, 120 patients were treated, with three-fourths receiving 5 days of study drug.
To me, that signifies a decrease in mortality!!
Less patients died than normal in the study compared to this very sick group of patients and most were getting Brilacidin!!
Although the primary endpoint was not met. It is possible a secondary endpoint such as mortality may have been met.
This was alluded to in the press release:
“The number of patients who died totaled eight, four each between active and placebo.”
“In the trial, 120 patients were treated, with three-fourths receiving 5 days of study drug.”
If the majority of patients were treated with Brilacidin - proportionately more patients should be dying in the Brilacidin group if mortality rates were equivalent.
However, it was equivalent numbers of patients dying (NOT equivalent percentages).
That translates to a potential reduction in mortality in the Brilacidin group!!
I truly and honestly wish primary endpoint was met and I will admit I was hopeful. However, I am NOT selling any shares until we get additional data of secondary endpoints.
Admittedly, I have been taking a bit of a hiatus from following the board, due to work obligations managing a very busy clinical practice.
I was very saddened to hear the passing of a legend on this board - govorchin. As many of us, who have been hear over 10+ years, we can attest to her insights and devotion. Our thoughts and prayers are with her and family.
We are certainly on the cusp of hearing some major news in the short course of a month. I am hopeful and eagerly awaiting what can be a life time changing event for myself financially (1+ million shares slowly but consistently accumulated over 10 years), but more importantly the life saving benefits to society at large (having a significant pan antiviral AND anti inflammatory treatment).
May god bless the participants of this board and IPIX!!
Would be fun if we can create a subgroup for shareholders in excess of 1M+ shares or shareholders that have held long and strong for 10+ years, and an extra special VIP club for shareholders that meet both of above.
Thanks for the info. I joined the Reddit subgroup and will be following there as well.
Excellent points, absolutely agree. I signed up based on kevetrin and I still believe with the right formulation and protocols it can be a huge winner.
I have said this before, but for those newcomers, I believe that in future people will be popping a baby kevetrin in the morning as a cancer prevention medication - the same way many patients with cardiac disease take a baby aspirin for heart disease. I am still optimistic on its potential.
Fortunately, with the acquisition of brilacidin from polymedix, we have more immediate potential for big gains that will help fund future kevetrin trials.
I have been fortunate to have been accumulating shares for over 10 years. Holding on to my shares tightly!!
I haven’t posted in quite some time...
Just want to self congratulate many of the longs that have held strong.
I have purchased my first shares over 10 years ago and for those of us initial believers we are getting much closer to the finish line.
Want to throw out a quick shoutout to KarinCa - she was one of the first people to write a comprehensive article of cellceutix that had placed the company on many peoples radar screens.
Thanks for everyone’s devotion and compassion - newcomers welcome!!
Trending higher! Any news we don’t know about?!?
Any speculation on 15% pop today?
Anyone recall timeline for current trials?
I’m extremely excited and optimistic. Some of us on this board have been following for 10+ years. Our patience and loyalty will likely be rewarded.
I had 50k shares in Nanoantibiotics - anyone know how many shares that is now after the reverse split that they had?
Correct. Market potential is unlimited. Additionally, don’t need such rigorous and expensive clinical trials by FDA. We can prove it’s less harmful than Clorox - that shouldn’t be difficult - this may be a total no brainer!!
Can this be used as a cleaning agent to disinfect surfaces? Less toxic than other cleaning agents!! Can we be adding this to swimming pools? Might be worthwhile exploring with commercial industrial vendors! Very very large commercial opportunity- can we send idea to company?
https://apnews.com/Globe%20Newswire/f07c903d06bbd10571e3875bbc933879
Hopefully news starts going mainstream!
I have been asked by several people on the board to message with my thoughts as I have not been contributing recently. My lack of posts on this board is due to my increased clinical and management responsibilities overseeing the care of thousands of patients. My optimism regarding the Brilacidin platform in the shorter term and kevetrin in the longer term remains very high. I remain a long term shareholder and keep steadily increasing my position. I eagerly await details of P3 for BOM. Wishing everyone a happy and healthy new year!
Congrats IPIX!
Job well done on the financing, although some may be critical, we need to be realistic and understand this is the cost of business, risk-reward is still potentially very favorable for investors who remain patient. I am eagerly looking forward to hearing upcoming news.
I have refrained from posting recently as not much new material information has been revealed. I still remain LONG and have been consistently adding to my position. As to the recent 8 and 10K, I very much believe the company is trying and ultimately will indeed make a deal to save the company and our risk/reward is still quite favorable. In regards to the termination of Dr. Menon, without going into details, I have a suspicion that with his departure we are one step closer to a deal. I have no specific basis for the above, except my overall experience in biotech involvement with both the academic and private sectors. Hopefully, over the next 2 months, more information will be revealed. In the meantime, I remain long and strong!
I am not an oncologist. However, I have both an MD and a PhD, my clinical practice as well as research background allows me to intersect in many diverse areas of medicine. A company like innovation pharmaceuticals really excites me as its drug pipeline is diverse and I have been fortunate to get in early and see its development from lab to clinical trials and hopefully to widespread clinical practice.
This is a bit off topic and not something I usually post about, so please indulge me. I had the privilege of taking care of a remarkable patient today. A young woman with a P53 genetic mutation resulting in her having breast cancer and severe uterine fibroids - potentially cancerous - at a very young age. She decided to undergo a mastectomy and hysterectomy along with radiation therapy. She has been warned that based on this mutation, she is at high risk of developing other cancers in the future. Her positive attitude and optimism was remarkable and truly inspirational. Hopefully, Kevetrin gets back on track in the near future and can be a cure for her as well as the many other victims of cancer.
I will be the first to admit that I didn’t predict this PR coming. Of course, we all wanted results and details. Although, this is a bit unorthodox, I am surprisingly satisfied as I interpret it as everything moving forward. Motivational milestones are fantastic. A big pharmaceutical deal likely in the works but negotiations will be from a better stronger position of strength and NOT desperation - it’s all about the optics. I remain long and strong, patience will be rewarded!
Just catching up on weekends posting, what is the email everyone is referring to from this past weekend?
Excellent point! I think we are very close to a deal being announced for Brilacidin with “negotiations” in play.
CDAs for prurisol likely and if trial results are good, negotiations to follow.
I remain long and strong. My 10 years of patience likely to be rewarded. Definitely, not leaving in the final hour. Good luck to all.
100% Agree. I significantly have reduced my posts and time spent reading this board - less and less productive. Been steadily accumulating shares at value prices as science progresses and risk/reward becomes more increasingly favorable.
I? hope everyone has had a great thanksgiving weekend! Hopefully, tomorrow will be the start of a very thankful 2018. Good luck to us longs!!
I have been sharing all of IPIX press releases on my Facebook and LinkedIn accounts and encourage others to do the same.
The PR strategy to raise awareness may be working. I have been sharing the press releases on my Facebook and linked in accounts and my friends are taking notice and interested in investing. They want to join me in an early retirement. I encourage others to do the same. Your friends will thank you in due time.
True that every investor has their own individualized plans. I have a lot of doctor friends that are highly interested in getting in. Some are waiting for positive Phase 2 results. They will then go in to capitalize on either a partnership or phase 3 results. I truly believe that we will be seeing a lot of activity and a substantial increase in share price over next 2 months.
Govorchin your frustration with the inability of patients to benefit from IPIX drugs are slightly misdirected. The FDA is the gatekeeper. Brilacidin phase 3 for ABSSI has potentially been held up because of their lack of appreciation as to the necessity for a new antibiotic. My assumptions based on reading between the lines, is that they are making the phase 3 trial more rigorous and expensive than it requires. As a physician, I can say that medicine is always a balance between benefit vs. risk. I bring up this pointy today, because yesterday’s PR I suspect was a message to the IBD community that IPIX plans to approach the FDA to expand the platform and they are hoping the FDA doesn’t make the trials to difficult and expensive. The IBD community will hopefully lobby and pressure the FDA to not obstruct IPIX and it’s desire to help patients (and investors) by getting Brilacidin to market.
Glad to hear they are advancing the Brilacidin GI platform - lots of potential. Good for patients and good for us investors.
I personally have no problems with these PRs.
Although it’s not new information to the many of us who are long time and committed followers, it can lead to increased and new awareness in the general population and investment community. In the age of “google it” patients, physicians, researchers, investors, etc. may come across this information in often unpredictable and indirect ways.
For me, it serves as affirmation that things remain on schedule and I don’t need to look up past PRs for expected timelines. I appreciate the follow up.
As always, I hope everyone remains optimistic and patient because I truly believe great things are on the horizon for IPIX.
We only need 1 successful trial to make a very nice return on our investment and I will likely retire extremely early. If all 3 are successful, my kids and grandchildren will all have very nice trust funds. Hopefully, they get rid of the estate tax;)
We don’t know that no partner reached out, we can only assume no deal has been finalized yet. With management being the largest shareholder - I assume they are evaluating all deals as they come. With waiting for additional positive trial results - we can keep negotiating a better deal. At some point, management will decide the benefit of a deal with increased funding can advance the company further along than what they can do by themselves. If we had no trial progression, I would be impatient for a deal. On the contrary, positive progress -considering the fact we are a small biotech has been truly remarkable. This will allow us the opportunity for life changing returns on our investment. These are complicated decisions and it is really naive for anyone to be passing judgment or an opinion - because we don’t have all the facts. No one is forcing anyone to invest here, it’s relatively high risk, but mitigated by the fact we have several trials and drugs and access to Aspire financing. My choice is to be patient and trust management. The likely reason for the persistent pessimism for those constantly in disagreement regardless of the announcement or clinical trial progress, is likely those who have a benefit for the share price to decline - short traders. Good luck to the Longs!
We are approaching a major transition point in this company’s history. I am proud to say that I have been following for about 10 years virtually since inception. My excitement and optimism has continually been exponentially increasing with each success. Good luck to all!
If our only lack of success, is not reporting an interim trial result, that does not diminish my optimism for the future. On the contrary, based on the successes of the past and multiple trials in progress - benefits/risks remain extremely favorable especially in light of the potential returns that can be achieved. To be honest, I expect we may hit another unanticipated bump along the way, being this is unchartered territory and not a BP in the driver seat. But I didn’t take this journey to make pennies, I am here for life changing and generational returns on my investment. Patience and tolerance will be greatly rewarded.
I am excited and optimistic for the 4th quarter and early 2018 trial results. In anticipation, just captured another 20k shares at these bargain prices, simply could not resist. Good luck to all LONGS!
Agree, I am actually thrilled to have Aspire on board buying at market prices whenever we decide we need more money to further the trials and pipeline. Big Pharma is no friend, but necessary to take our drugs to market with their large salesforce. I am happy to wait for a bigger and better deal as our drugs mature. I have a very large stake in this company and looking for transformational wealth for me and my family. A deal with BP now, would be nice and perhaps a 10x return, but a deal at a later time, can potentially bring 100x returns. I remain optimistic, long, and strong.
I personally have a lot of experience presenting research and clinical data throughout my education and current career. These presentations take a significant amount of effort and preparation to ensure quality control and accuracy. Therefore, I assume prurisol interim data will not be presented at this upcoming conference. I expect a separate PR in the next 2 to 3 weeks. It is much easier to put it in a PR than to have the slides formatted to look professional.
I have been following the board reads as well. Lots of people sitting on sidelines awaiting news of trial results. Any positive trial results will likely propel share price significantly. Fortunately, we have 3 drugs in pipeline, so even if one result is not as positive as we are hoping, we have 2 other drugs in pipeline. Risk/reward is extremely favorable.